Breaking News

India's COVID-19 Vaccine Effective Against Omicron

January 12, 2022 • 8:23 am CST
(Precision Vaccinations)

Pennsylvania-based Ocugen, Inc. and Bharat Biotech today announced results from a study conducted at Emory University in Atlanta, GA, demonstrating that sera from subjects who received a booster dose of candidate vaccine COVAXIN™ (BBV152) six months after getting a primary two-dose series of COVAXIN neutralized the SARS-CoV-2 Omicron and Delta variants.

Earlier studies demonstrated the neutralizing potential of COVAXIN against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta, and Kappa.

"As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern," said Mehul Suthar, Ph.D. Assistant Professor, Emory Vaccine Center, and who led the laboratory analysis.

"Data from this preliminary (phase 1/2) analysis show individuals receiving a booster dose of COVAXIN have a significant immune response to both the Omicron and Delta variants."

"These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations," concluded Dr. Suthar's press release comments.

COVAXIN is formulated uniquely such that the same dosage can be administered to adults and children alike. In addition, the same vaccine doses can also be used for two-dose primary immunization in adults and children and booster dose vaccinations, making it truly a universal vaccine.

COVAXIN is an investigational vaccine candidate product in the U.S, currently under review by the U.S. Food and Drug Administration for emergency use authorization (EUA) for children 2-18 years of age.

With more than 180 million doses administered to adults and children outside the U.S., COVAXIN is currently authorized under emergency use in more than 20 countries, and emergency use authorization is in process in more than 60 other countries.

The World Health Organization recently added COVAXIN to its list of vaccines authorized for emergency use. 

Ocugen, Inc. is a biopharmaceutical company located in Malvern, PA, focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.